NCT04645667View on ClinicalTrials.gov

Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT)

CompletedOBSERVATIONAL
Enrollment

38

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

October 15, 2023

Study Completion Date

October 15, 2023

Conditions
Acute GVHD
Interventions
DRUG

Tacrolimus

Patients will be enrolled into this group if they receive tacrolimus per standard of care. This is an observational study and no interventions will be made.

Trial Locations (1)

27514

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

University of North Carolina, Chapel Hill

OTHER

lead

UNC Lineberger Comprehensive Cancer Center

OTHER

NCT04645667 - Tacrolimus in Allogeneic Hematopoietic Stem Cell Transplant (HCT) | Biotech Hunter | Biotech Hunter